Oncotype DX for the prediction of recurrence of invasive breast cancer

Record ID 32013000311
English
Authors' recommendations: It is estimated that in 2012, 226,870 new cases of invasive breast cancer will be diagnosed in the United States and 39,510 American women will die from the disease. While breast cancer is common, if it is identified early enough (when localized) the 5-year survival rate for women is 98.4%. However, the survival rate is lower if the cancer has spread to the lymph nodes (i.e., nodepositive [N+]), and drops dramatically to 23.8% if it has metastasized. The use of adjuvant chemotherapy in patients with breast cancer to reduce the risk of cancer recurrence following surgical resection has resulted in improvements in both disease-free survival and overall survival for women. However, because the majority of women that receive adjuvant chemotherapy will not benefit from it while being exposed to the associated toxicities, physicians and patients must balance the benefits and risks of adjuvant chemotherapy in choosing whether to administer it. Commonly used prognostic factors that are used to help guide administration of adjuvant chemotherapy are: age; menopausal status; cancer stage and location; histologic and nuclear tumor grade; estrogen (ER), progesterone (PR), and HER2 (ERBB2) receptor status; and measures of proliferation of the tumor. Because of the complexity of making these decisions, several guidelines and prognostic models are used to identify patients at high risk for disease-specific mortality or greater chance of recurrence. The Oncotype DX assay has been developed to predict which women are at greater risk of recurrence of invasive breast cancer and are therefore more likely to benefit from treatment with adjuvant chemotherapy.
Details
Project Status: Completed
Year Published: 2012
URL for published report: The report may be purchased from:http://www.hayesinc.com/hayes/crd/?crd=11163
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: United States
MeSH Terms
  • Gene Expression Profiling
  • Neoplasm Recurrence, Local
  • Reverse Transcriptase Polymerase Chain Reaction
Contact
Organisation Name: HAYES, Inc.
Contact Address: 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name: saleinfo@hayesinc.com
Contact Email: saleinfo@hayesinc.com
Copyright: 2013 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.